ALISON MOE: Open Payments
NPI 1417227448 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$205,153 in 470 payments from 23 companies in 2025. Trend: 2023 $22,436 · 2024 $130,622 · 2025 $205,153
Speaker / faculty: $136,637Travel & lodging: $44,789Consulting: $12,644Food & beverage: $11,084
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 198 | $130,642 |
| Madrigal Pharmaceuticals | 153 | $68,690 |
| Genentech USA, Inc. | 6 | $2,969 |
| Celltrion USA Inc. | 8 | $603 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $293 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $254 |
| Janssen Biotech, Inc. | 17 | $253 |
| GlaxoSmithKline, LLC. | 1 | $250 |
| Ardelyx, Inc. | 12 | $221 |
| Regeneron Healthcare Solutions, Inc. | 9 | $217 |
Products named: SKYRIZI, REZDIFFRA, RINVOQ, DUPIXENT, ZYMFENTRA, TREMFYA, XIFAXAN, IBSRELA.
Industry payments across GA — which companies pay providers there.
